The dysregulation of the PI3K/AKT/mTOR pathway in ASCC, driven by IGF2 from CAFs, highlights the potential of IGF2/IGF1R inhibitors as targeted treatments for this rare cancer. This evidence concerns the gene IGF2 and cancer.